Suzanne Baker
Overview
Explore the profile of Suzanne Baker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1030
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coughlan G, Rubinstein Z, Klinger H, Lopez K, Hsieh S, Boyle R, et al.
Sci Adv
. 2025 Mar;
11(10):eadt1288.
PMID: 40043125
Elucidating the downstream impact of exogenous hormones on the aging brain will have far-reaching consequences for understanding why Alzheimer's disease (AD) predominates in women almost twofold over men. We tested...
2.
Ruiz-Uribe N, Manser P, Butcher B, Li Y, Blendstrup M, Baker S, et al.
J Alzheimers Dis
. 2025 Jan;
103(2):465-475.
PMID: 39801050
Background: In Alzheimer's disease (AD), tau and white matter lesion pathology are associated with clinical severity and subsequent decline, but their relative relationships with clinical assessments remain uncertain. Objective: To...
3.
Andrews J, Lloyd M, Neuhauser S, Bundy M, Jocoy E, Airhart S, et al.
Bioinformatics
. 2024 Nov;
40(12).
PMID: 39589865
Summary: Short tandem repeat (STR) profiling is commonly performed for authentication of biomedical models of human origin, yet no tools exist to easily compare sets of STR profiles to each...
4.
Denkinger M, Baker S, Harrison T, Chadwick T, Jagust W
Neurobiol Aging
. 2024 Nov;
146:15-23.
PMID: 39571410
Blood-brain barrier disruption (BBBd) occurs in aging, particularly in regions vulnerable to Alzheimer's disease (AD) pathology. However, its relationship to pathological protein accumulation, neurodegeneration, and cognitive impairment in normal aging...
5.
Leuzy A, Raket L, Villemagne V, Klein G, Tonietto M, Olafson E, et al.
Alzheimers Dement
. 2024 Jul;
20(9):5833-5848.
PMID: 39041435
Introduction: Tau-positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer...
6.
7.
Denkinger M, Baker S, Inglis B, Kobayashi S, Juarez A, Mason S, et al.
PLoS One
. 2024 Jun;
19(6):e0299764.
PMID: 38837947
Background: Increased blood-brain barrier permeability (BBBp) has been hypothesized as a feature of aging that may lead to the development of Alzheimer's disease (AD). We sought to identify the brain...
8.
Bohorquez S, Baker S, Manser P, Tonietto M, Galli C, Wildsmith K, et al.
Front Neuroimaging
. 2024 Apr;
3:1355402.
PMID: 38606196
Purpose: We evaluated the impact of partial volume correction (PVC) methods on the quantification of longitudinal [F]GTP1 tau positron-emission tomography (PET) in Alzheimer's disease and the suitability of describing the...
9.
Young P, Heeman F, Axelsson J, Collij L, Hitzel A, Sanaat A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Oct;
51(3):734-748.
PMID: 37897616
Purpose: To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [F]flutemetamol and [F]florbetaben. Methods: Cognitively impaired and unimpaired individuals (N ...
10.
Roberts H, Ji S, Picca A, Sanson M, Garcia M, Snuderl M, et al.
Acta Neuropathol
. 2023 Oct;
146(6):849-852.
PMID: 37851269
No abstract available.